Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China
| Autor: | Shusen Wang, Xiaoyu Teng, Yin-Duo Zeng, Bing Bai, Zhongyu Yuan, Roujun Peng, Dong-Geng Liu, Tao Qin, Yanxia Shi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
hormone receptor status
Oncology medicine.medical_specialty Pathology endocrine therapy business.industry Hazard ratio Endocrine therapy ECOG Performance Status General Medicine Disease medicine.disease Metastatic breast cancer Metastasis surgery anti-HER2 therapy Southern china Clinical Research Internal medicine medicine brain metastasis skin and connective tissue diseases business Brain metastasis |
| Zdroj: | Archives of Medical Science : AMS |
| ISSN: | 1734-1922 |
| DOI: | 10.5114/aoms.2015.52356 |
| Popis: | Introduction The aim of the study was to analyze clinicopathologic characteristics and survival and to identify prognostic factors for Chinese patients with HER2-positive metastatic breast cancer. Material and methods A total of 243 patients with HER2-positive metastatic breast cancer, treated during the period 2002 to 2009, were followed up from initial disease diagnosis to death or date of last follow-up (December 2011). Cumulative survival curves were created using Kaplan-Meier analysis with the log-rank test. Prognostic factors were analyzed by univariate and multivariate Cox proportional hazards regression analysis. Results During follow-up, 205 patients died, with a median OS of 27 months (95% CI: 23.5, 30.5 months), and the 1-, 3-, and 5-year survival rates were 84.4%, 38.6%, and 18.1%, respectively. The median OS of HR+ patients was significantly higher than that of HR– patients (p < 0.001). Surgery (hazard ratio = 0.60, p = 0.002), endocrine therapy (hazard ratio = 0.53, p < 0.01), and anti-HER2 therapy (hazard ratio = 0.63, p = 0.003) were favorable independent prognostic factors for patients with HER2-positive metastatic breast cancer. Conclusions These results indicated that surgical intervention, endocrine therapy, and anti-HER2 therapy were good for these HER2 positive patients with metastatic breast cancer, but ECOG performance status < 1 and metastasis to brain were unfavorable independent prognostic factors. HR status was not an independent prognostic factor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|